[go: up one dir, main page]

NO20045034L - Transdermale analgetiske systemer med redusert misbrukspotensiale - Google Patents

Transdermale analgetiske systemer med redusert misbrukspotensiale

Info

Publication number
NO20045034L
NO20045034L NO20045034A NO20045034A NO20045034L NO 20045034 L NO20045034 L NO 20045034L NO 20045034 A NO20045034 A NO 20045034A NO 20045034 A NO20045034 A NO 20045034A NO 20045034 L NO20045034 L NO 20045034L
Authority
NO
Norway
Prior art keywords
transdermal analgesic
abuse potential
analgesic systems
reduced abuse
antagonist
Prior art date
Application number
NO20045034A
Other languages
English (en)
Inventor
Robert M Gale
Jay Audett
Thomas M Stein
Jane Stepic
Joseph B Phipps
Michel Cormier
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of NO20045034L publication Critical patent/NO20045034L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives et transdermalt, analgetisk system med et redusert potensiale mot misbruk, der systemet tilveiebringer kontrollert frigivning av antagonisten i en grad tilstrekkelig til å tilveiebringe et misbruksbegrensende frigivningshastighetsforhold mellom antagonist og analgetikum når doseringsformen misbrukes.
NO20045034A 2002-04-23 2004-11-19 Transdermale analgetiske systemer med redusert misbrukspotensiale NO20045034L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37511002P 2002-04-23 2002-04-23
PCT/US2003/012418 WO2003090729A1 (en) 2002-04-23 2003-04-22 Transdermal analgesic systems with reduced abuse potential

Publications (1)

Publication Number Publication Date
NO20045034L true NO20045034L (no) 2005-01-19

Family

ID=29270594

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045034A NO20045034L (no) 2002-04-23 2004-11-19 Transdermale analgetiske systemer med redusert misbrukspotensiale

Country Status (20)

Country Link
US (2) US8440220B2 (no)
EP (1) EP1513507B1 (no)
JP (2) JP2005526839A (no)
KR (1) KR20050050615A (no)
CN (2) CN1720028A (no)
AR (1) AR039336A1 (no)
AT (1) ATE501712T1 (no)
AU (2) AU2003221752A1 (no)
CA (1) CA2496454A1 (no)
DE (1) DE60336394D1 (no)
ES (1) ES2361068T3 (no)
IL (1) IL164760A0 (no)
MX (1) MXPA04010612A (no)
NO (1) NO20045034L (no)
NZ (1) NZ535971A (no)
PE (1) PE20031016A1 (no)
TW (1) TW200404581A (no)
UY (1) UY27773A1 (no)
WO (1) WO2003090729A1 (no)
ZA (1) ZA200409396B (no)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
CZ307857B6 (cs) * 2001-03-16 2019-07-03 Alza Corporation Transdermální náplast pro podávání fentanylu nebo jeho analogu
TW200404581A (en) * 2002-04-23 2004-04-01 Alza Corp Transdermal analgesic systems with reduced abuse potential
EP2422773A3 (en) * 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
US20040219195A1 (en) * 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
MY141815A (en) * 2003-04-30 2010-06-30 Purdue Pharma Lp Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
EP2269606A3 (en) * 2003-10-30 2012-04-25 ALZA Corporation Transdermal analgesic systems having reduced abuse potential
US7867511B2 (en) * 2004-01-23 2011-01-11 Travanti Pharma Inc. Abuse potential reduction in abusable substance dosage form
US8535711B2 (en) * 2004-01-23 2013-09-17 Teikoku Pharma Usa, Inc. Medication disposal system
ES2324719T3 (es) * 2004-02-23 2009-08-13 Euro-Celtique S.A. Dispositivo de administracion transdermica de opioides con resistencia al abuso.
US20050202073A1 (en) * 2004-03-09 2005-09-15 Mylan Technologies, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
US9205062B2 (en) 2004-03-09 2015-12-08 Mylan Pharmaceuticals, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
DE102004019916A1 (de) * 2004-04-21 2005-11-17 Grünenthal GmbH Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster
KR20070053267A (ko) * 2004-08-20 2007-05-23 쓰리엠 이노베이티브 프로퍼티즈 컴파니 반투명 보호 필름을 갖는 경피 약물 전달 장치
CA2580329C (en) 2004-09-13 2015-01-06 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US8252320B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
US8246977B2 (en) 2004-10-21 2012-08-21 Durect Corporation Transdermal delivery systems
US7827983B2 (en) * 2004-12-20 2010-11-09 Hewlett-Packard Development Company, L.P. Method for making a pharmaceutically active ingredient abuse-prevention device
EP1835020A4 (en) 2005-01-07 2011-06-15 Universal Bio Research Co Ltd VEHICLE PLATE WITH VEHICLE, APPARATUS AND METHOD FOR PROCESSING THE VEHICLE
TW200640526A (en) * 2005-02-24 2006-12-01 Alza Corp Transdermal electrotransport drug delivery systems with reduced abuse potential
US20070053965A1 (en) * 2005-02-25 2007-03-08 Gruenenthal Gmbh Kit comprising a plaster, optionally containing an active substance, and an agent that at least partially reduces skin irritation
US20060257460A1 (en) * 2005-05-13 2006-11-16 Jansen Rolf R Multilayer drug delivery system with barrier against antagonist exposure
PT1895994E (pt) * 2005-05-13 2010-12-03 Alza Corp Sistema de administração de medicamentos de camada múltipla com barreira contra o fluxo de material do reservatório
CN101009530B (zh) * 2006-01-23 2012-02-15 华为技术有限公司 支持组播类业务的无源光网络、复用/解复用器及方法
ES2636657T3 (es) 2006-06-19 2017-10-06 Alpharma Pharmaceuticals Llc Composición farmacéutica
AU2007322269A1 (en) * 2006-10-11 2008-05-29 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
US20090258061A1 (en) * 2007-10-15 2009-10-15 Johnson & Johnson Once-a-day replacement transdermal administration of fentanyl
US8165669B2 (en) * 2007-12-05 2012-04-24 The Invention Science Fund I, Llc System for magnetic modulation of neural conduction
US8170660B2 (en) 2007-12-05 2012-05-01 The Invention Science Fund I, Llc System for thermal modulation of neural activity
US8195287B2 (en) * 2007-12-05 2012-06-05 The Invention Science Fund I, Llc Method for electrical modulation of neural conduction
US8180446B2 (en) * 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method and system for cyclical neural modulation based on activity state
US8170658B2 (en) 2007-12-05 2012-05-01 The Invention Science Fund I, Llc System for electrical modulation of neural conduction
US8180447B2 (en) 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method for reversible chemical modulation of neural activity
US20090149797A1 (en) * 2007-12-05 2009-06-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System for reversible chemical modulation of neural activity
US8160695B2 (en) * 2007-12-05 2012-04-17 The Invention Science Fund I, Llc System for chemical modulation of neural activity
US8165668B2 (en) * 2007-12-05 2012-04-24 The Invention Science Fund I, Llc Method for magnetic modulation of neural conduction
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
CA2709905A1 (en) * 2007-12-17 2009-06-25 Alfred Liang Abuse-resistant oxycodone composition
WO2009088673A2 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
JP2011513287A (ja) * 2008-02-28 2011-04-28 シントロファーマ リミテッド 医薬品組成物
US20090246265A1 (en) * 2008-03-26 2009-10-01 Alltranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
US20100221313A1 (en) * 2008-12-01 2010-09-02 Innovative Pharmaceuticals, Llc Transdermal reservoir patch
CN101434708B (zh) * 2008-12-19 2012-01-11 成都中科来方能源科技有限公司 水性聚合物改性微孔聚烯烃隔膜及其制备方法和用途
WO2010100414A1 (en) 2009-03-04 2010-09-10 Orexo Ab Abuse resistant formulation
EA027618B1 (ru) 2009-05-08 2017-08-31 Эмпликюре Аб Композиция для непрерывной доставки лекарственного средства, содержащая геополимерное связующее
DE102009036485B4 (de) * 2009-08-07 2012-10-04 Lts Lohmann Therapie-Systeme Ag Mittel zur zerstörenden Entsorgung von medizinischen Wirkstoffen in transdermalen therapeutischen Systemen
ES2592277T3 (es) * 2010-04-02 2016-11-29 Buzzz Pharmaceuticals Limited Formulaciones transdérmicas disuasorias del abuso de agonistas y agonistas-antagonistas opiáceos
JP5927506B2 (ja) 2010-04-13 2016-06-01 レルマダ セラピューティクス、インク． １−メチル−２’，６’−ピペコロキシリダイドの皮膚医薬組成物および使用方法
ES2658913T3 (es) 2010-09-07 2018-03-12 Emplicure Ab Dispositivo de administración transdérmica de un fármaco
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
EP2760412B1 (en) 2011-09-30 2017-07-19 Verde Environmental Technologies, Inc. General medication disposal system
WO2013049380A1 (en) 2011-09-30 2013-04-04 Teikoku Pharma Usa, Inc. Transdermal patch disposal system
CN115444659A (zh) * 2014-01-22 2022-12-09 4P治疗公司 滥用和误用制止透皮系统
US11607026B2 (en) * 2014-05-30 2023-03-21 Johnson & Johnson Consumer Inc. Device for delivery of skin care composition
CA2955241C (en) 2014-07-18 2023-03-28 Buzzz Pharmaceuticals Limited Oxymorphone transdermal patch
EP3197275B1 (en) 2014-09-24 2021-11-24 Pain Therapeutics, Inc. 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal
US10010543B1 (en) * 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
WO2016145373A1 (en) 2015-03-12 2016-09-15 Chrono Therapeutics Inc. Craving input and support system
EP3352822B1 (en) 2015-09-24 2022-07-27 Pain Therapeutics, Inc. Cocrystals of naloxone and naltrexone
GB201600919D0 (en) * 2016-01-18 2016-03-02 Buzzz Pharmaceuticals Ltd Transdermal patch
EP3565617A1 (en) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US10300454B2 (en) 2017-04-18 2019-05-28 Breakthrough Technologies, Llc. Sulfur production
CN117462324A (zh) 2018-03-07 2024-01-30 Soovu实验室公司 用于通过刺激热觉纤维改善疼痛缓解的系统和方法
US11389844B2 (en) 2018-03-20 2022-07-19 Verde Environmental Technologies, Inc. Blister pack disposal system
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
WO2020009685A1 (en) 2018-07-02 2020-01-09 John Tang Transdermal dosage form
WO2020008366A1 (en) 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal dosage form
WO2020008370A1 (en) 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal patch
DE102018216244A1 (de) * 2018-09-24 2020-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit Barriereschicht
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
JP6912122B2 (ja) * 2019-02-28 2021-07-28 日本臓器製薬株式会社 経皮投与製剤
CN112810171B (zh) * 2021-01-22 2025-10-31 东莞市高贝瑞自动化科技有限公司 一种耳机套全自动生产线
WO2022249748A1 (ja) * 2021-05-24 2022-12-01 住友精化株式会社 ゲル状組成物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493657A (en) * 1961-03-14 1970-02-03 Mozes Juda Lewenstein Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US5310559A (en) * 1982-09-01 1994-05-10 Hercon Laboratories Corporation Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporating a rate controlling member which comprises an alkylene-alkyl acrylate copolymer
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5006342A (en) * 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
US5186939A (en) * 1987-04-23 1993-02-16 Cygnus Therapeutic Systems Laminated composite for transdermal administration of fentanyl
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5762952A (en) * 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
US5882676A (en) * 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
WO1997004835A1 (de) * 1995-07-28 1997-02-13 Novartis Ag Transdermales system
US6103258A (en) 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
US5783583A (en) 1996-04-12 1998-07-21 Simon; David Lew 17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol, hydrochloride salt for the purpose of rapid narcotic detoxification
TW411277B (en) * 1996-05-13 2000-11-11 Hisamitsu Pharmaceutical Co Percutaneous tape preparation containing fentanyl
US5985317A (en) * 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
ATE229817T1 (de) * 1996-10-24 2003-01-15 Alza Corp Penetrationsfördernde substanzen für die transdermale verabreichung von wirkstoffen, vorrichtungen und verfahren zur herstellung
DE19653606A1 (de) * 1996-12-20 1998-06-25 Roehm Gmbh Haft- und Bindemittel aus (Meth)acrylatpolymer, organischer Säure und Weichmacher
DE19653605C2 (de) * 1996-12-20 2002-11-28 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
IT1294748B1 (it) * 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
US6835194B2 (en) * 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
SI1299104T1 (sl) 2000-02-08 2009-10-31 Euro Celtique Sa Oralne formulacije opioidnih agonistov, varne pred zlorabo
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
CZ307857B6 (cs) * 2001-03-16 2019-07-03 Alza Corporation Transdermální náplast pro podávání fentanylu nebo jeho analogu
PT2062573E (pt) 2001-05-01 2012-01-11 Euro Celtique Sa Sistemas transdérmicos que contêm opióides que resistem a violação
TW200404581A (en) * 2002-04-23 2004-04-01 Alza Corp Transdermal analgesic systems with reduced abuse potential
WO2004017941A2 (en) * 2002-08-20 2004-03-04 Euro-Celtique, S.A. Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
EP2269606A3 (en) * 2003-10-30 2012-04-25 ALZA Corporation Transdermal analgesic systems having reduced abuse potential

Also Published As

Publication number Publication date
AU2003221752A1 (en) 2003-11-10
AR039336A1 (es) 2005-02-16
US20040013716A1 (en) 2004-01-22
TW200404581A (en) 2004-04-01
EP1513507B1 (en) 2011-03-16
MXPA04010612A (es) 2005-07-14
NZ535971A (en) 2007-07-27
UY27773A1 (es) 2003-09-30
DE60336394D1 (de) 2011-04-28
CA2496454A1 (en) 2003-11-06
IL164760A0 (en) 2005-12-18
US20130251760A1 (en) 2013-09-26
US8440220B2 (en) 2013-05-14
WO2003090729A1 (en) 2003-11-06
CN101406703A (zh) 2009-04-15
JP2005526839A (ja) 2005-09-08
ZA200409396B (en) 2006-07-26
CN1720028A (zh) 2006-01-11
EP1513507A1 (en) 2005-03-16
KR20050050615A (ko) 2005-05-31
ATE501712T1 (de) 2011-04-15
AU2009202407A1 (en) 2009-07-09
US8747889B2 (en) 2014-06-10
JP2011057684A (ja) 2011-03-24
JP5453211B2 (ja) 2014-03-26
PE20031016A1 (es) 2003-11-29
ES2361068T3 (es) 2011-06-13

Similar Documents

Publication Publication Date Title
NO20045034L (no) Transdermale analgetiske systemer med redusert misbrukspotensiale
WO2005044243A3 (en) Transdermal analgesic systems having reduced abuse potential
CY1105138T1 (el) Θepμου-τηγματος-δθς για χορηγηση ροτιγκοτινης
DK1213015T3 (da) Oralt farmaceutisk præparat med forsinket frigivelse af protonpumpeinhibitorer
AU6517596A (en) Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors
BRPI0412557A (pt) forma de dosagem farmacêutica de eventos cardiovasculares
MX2023000630A (es) Inhibidor de rock, y método de preparacion para el mismo y uso del mismo.
ATE303178T1 (de) Acc-hemmer
NZ610790A (en) Transdermal methods and systems for the delivery of anti-migraine compounds
MY141196A (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
NO985964L (no) Administrasjonskur for H+, K+ -ATPase-inhibitorer
DE60327883D1 (de) Analgetische verwendung von (s)-norketamin
NO20093060L (no) Spirosykliske sykloheksanderivater
ATE368454T1 (de) Transdermal granisetron
WO2004103288A3 (en) Method of preventing recurrent miscarriages
ATE400258T1 (de) Transdermales buprenorphin-dosierschema zwecks schmerzstillung
Sawyers et al. Hematologic and Cytogenetic Responses in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study.
NO20072832L (no) Smertestillende middel
WO2005077365A3 (en) Novel uses for proton pump inhibitors
ATE199496T1 (de) Transdermale darreichungsform mit antihistaminisch wirksamen loratidinmetabolit
EP0661050A4 (en) ANALGESIC.
IS7383A (is) Skammtaform með stýrða lyflosun til inngjafar
TW200633720A (en) Medicinal composition for diabetic
SE0203410D0 (sv) New use
TW200630109A (en) Drug for external use and adhesive patch

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application